Patents by Inventor Keeve D. Jaffe

Keeve D. Jaffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically engineered enzymes and their conjugates for diagnostic assays
    Patent number: 5843634
    Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Elaine M Brate, Catherine A. Brennan, Dominique P. Bridon, Keeve D. Jaffe, Grant A. Krafft, Wlodzimierz Mandecki, Steven C. March, John C. Russell, Vincent T. Yue
  • Hepatitis GB Virus synthetic peptides and uses thereof
    Patent number: 5843450
    Abstract: Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV peptides.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: George J. Dawson, Tami J. Pilot-Matias, Dominique P. Bridon, Pamella A. Schroeder-Poliak, Mark F. Knigge, Keeve D. Jaffe, Isa K. Mushahwar
  • Peptides for HIV-1 detection
    Patent number: 5800983
    Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: September 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Dominique P. Bridon, Isaac S.-Y. Sze, deceased, David J. Daghfal, Keeve D. Jaffe, Tracey L. Colpitts
  • Peptides for HIV-1 detection
    Patent number: 5624797
    Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 29, 1997
    Assignee: Abbott Laboratories
    Inventors: Dominique P. Bridon, Isaac S.-Y. Sze, deceased, David J. Daghfal, Keeve D. Jaffe, Tracey L. Colpitts